ArticleJournal of lipid research2020
Membrane-bound
Open access · hybridAbstract read
In one paragraph
Article in Journal of lipid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Insulin resistance in the 21st century: new takes on an old problem-2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum.Diabetologia · 2026Review
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Impact of Elovl3 Suppression on Sleep Deprivation-Induced Hepatic Steatosis and Glucose Intolerance in Mice.Cureus · 2026Article
- Lipidomics and temporal-spatial distribution of organelle lipid.Journal of biological methods · 2025Review
- Establishment and Validation of Lactate Metabolism-Related Genes as a Prognostic Model for Gastric Cancer.Current molecular medicine · 2025Article
- Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease.Cell metabolism · 2024Article
- Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter 2 Inhibitor Therapy.Journal of clinical medicine · 2023Review
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy.Journal of translational medicine · 2023Review
- Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR.Cell death & disease · 2022Article
- Postprandial Plasma Lipidomics Reveal Specific Alteration of Hepatic-derived Diacylglycerols in Nonalcoholic Fatty Liver Disease.Gastroenterology · 2022Article
- Sex- and strain-specific effects of mitochondrial uncoupling on age-related metabolic diseases in high-fat diet-fed mice.Aging cell · 2022Article
- Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.Diagnostics (Basel, Switzerland) · 2021Review
- The insulin centennial-100 years of milestones in biochemistry.The Journal of biological chemistry · 2021Article
- Review
- Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH.Molecular metabolism · 2021Review
- The insulin centennial-100 years of milestones in biochemistry.Journal of lipid research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Abudukadier AbuliziDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Daniel F VatnerDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Zhang YeDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Yongliang WangDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Joao-Paulo CamporezDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Dongyan ZhangDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Mario KahnDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Kun LyuDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Alaa SirwiDepartments of Cell Biology and Pediatrics, SUNY Downstate Medical Center, Mineola, NY, USA.
Gary W ClineDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
M Mahmood HussainDepartments of Cell Biology and Pediatrics, SUNY Downstate Medical Center, Mineola, NY, USA; Department of Foundations of Medicine, NYU Long Island School of Medicine, Mineola, NY, USA.
Patricia AspichuetaDepartment of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Biocruces Research Institute, Barakaldo, Spain.
Varman T SamuelDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Veterans Affairs Medical Center, West Haven, CT, USA.
Gerald I ShulmanDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT, USA. Electronic address: gerald.shulman@yale.edu.
Yale University · USLong Island University · USSUNY Downstate Health Sciences University · USUniversity of the Basque Country · ESVeterans Health Administration · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Richard A Flavell · 1993 to 2026
$44.0MYale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI MICHAEL H NATHANSON · 1986 to 2026
$31.1MEffects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin ResistanceR01DK113984 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2017 to 2021
$3.7MDevelopment of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human PrimatesR01DK119968 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2019 to 2024
$2.7MMicrobiome origins and insulin regulatory responses of the short chain fatty acid acetateR01DK114793 · NIDDK · YALE UNIVERSITY · PI GOODMAN, ANDREW L, SHULMAN, GERALD I · 2018 to 2021
$2.4MGlucagon Regulation of Hepatic Mitochondrial Activity and Glucose Metabolism by InsP3R-1R01DK116774 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2018 to 2021
$1.7MEffects of miR-30c deficiency on plasma cholesterol and atherosclerosisR01HL137202 · NHLBI · NYU WINTHROP HOSPITAL · PI HUSSAIN, M MAHMOOD · 2017 to 2020
$1.5MCircadian Regulation of Lipoprotein AssemblyR01DK121490 · NIDDK · NYU WINTHROP HOSPITAL · PI HUSSAIN, M MAHMOOD · 2019 to 2021
$1.0MIn vivo regulation of lipid flux in the etiology of NAFLD and Insulin ResistanceK23DK102874 · NIDDK · YALE UNIVERSITY · PI VATNER, DANIEL · 2015 to 2019
$776kCellular mechanisms for increased gluconeogenesis in type 2 diabetes mellitus: the role of lipid induced pyruvate carboxylase acetylation in increasing hepatic gluconeogenic capacity.I01BX000901 · VA · VA CONNECTICUT HEALTHCARE SYSTEM · PI SAMUEL, VARMAN T · 2012 to 2020
–MicroRNAs regulating plasma LDL and HDLI01BX004113 · VA · VA NEW YORK HARBOR HLTHCARE/SYS/BROOKLYN · PI HUSSAIN, M MAHMOOD · 2018 to 2021
–BLRD VA I01 BX000901BLRD VA I01 BX004113NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL137202NIDDK NIH HHS K23 DK102874NIDDK NIH HHS P30 DK034989NIDDK NIH HHS P30 DK045735NIDDK NIH HHS R01 DK113984NIDDK NIH HHS R01 DK114793NIDDK NIH HHS R01 DK116774NIDDK NIH HHS R01 DK119968NIDDK NIH HHS R01 DK121490
Abstract
Microsomal triglyceride transfer protein (MTTP) deficiency results in a syndrome of hypolipidemia and accelerated NAFLD. Animal models of decreased hepatic MTTP activity have revealed an unexplained dissociation between hepatic steatosis and hepatic insulin resistance. Here, we performed comprehensive metabolic phenotyping of liver-specific MTTP knockout (L-
Indexed as
Carrier ProteinsDiglyceridesFatty LiverInsulin ResistanceLiverMice, KnockoutAnimalsCell MembraneMaleMice1,2-diacylglycerolCarrier ProteinsDiglyceridesmicrosomal triglyceride transfer proteindiabetesdrug therapylipidsliverliver microsomal triglyceride transfer proteinliver-targeted mitochondrial uncouplermetabolic diseasenonalcoholic fatty liver disease
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.